

August 2022 ~ Resource #380823

## Chronic Meds in the Elderly: Taking a “Less Is More” Approach

modified April 2025

Polypharmacy is the number one predictor of adverse drug events (e.g., falls, hospitalization, death).<sup>1,8</sup> For this reason, the concept of “deprescribing” unneeded or potentially harmful medications has been suggested.<sup>19</sup> The chart below provides considerations and resources to help you identify medications that may need to be deprescribed, and tips on how to do so.

| Disorder or Treatment                            | Considerations for Elderly Patients and Resources   |
|--|---|
| <p><b>General</b></p> <p><i>Continued...</i></p> | <ul style="list-style-type: none"> <li>• Be aware of meds that should generally be avoided or minimized in the elderly due to their risks:               <ul style="list-style-type: none"> <li>• Our chart, <i>Potentially Harmful Drugs in the Elderly: Beers List</i>, summarizes the Beers list and gives alternatives.</li> <li>• Avoid drugs with moderate or high anticholinergic activity, using our chart, <i>Drugs With Anticholinergic Activity</i>.</li> </ul> </li> <li>• Help improve med safety in elderly patients by preventing med errors. Pharmacists can get our CE, <i>Preventing Medication-Related Errors</i>.</li> <li>• Ask patients to bring in all of their meds so you can document what they are actually taking (“brown bag” review).<sup>17</sup> <ul style="list-style-type: none"> <li>• Confirm that each medication has an indication and look for medications that may be used to treat avoidable side effects from another drug.<sup>19</sup> For example, oxybutynin may be used to treat urinary incontinence caused by donepezil.</li> <li>• Identify meds for which the harms may be outweighing the benefit for the patient at this time.<sup>19</sup></li> <li>• Consider the appropriateness of any drug prescribed to treat a side effect of another drug.<sup>19</sup></li> <li>• Stop one med at a time.<sup>19</sup> Consider starting with meds with the highest risk/benefit ratio, which are often meds used for prevention of chronic illness (e.g., statins).<sup>19</sup> Taper if necessary.<sup>19</sup> When deprescribing, be aware of Common Oral Medications that May Need Tapering. This chart provides the rationale for tapering and suggested tapering strategies.</li> <li>• Monitor the patient for worsening of the condition that was being treated, and withdrawal symptoms.<sup>19</sup></li> <li>• Ask about the use of over-the-counter medications, vitamins, or supplements, which may cause side effects or not be adding benefit.</li> </ul> </li> <li>• Consider underlying causes, such as undertreated conditions, before adding a medication. For example, unmanaged pain or dehydration may lead to agitation.</li> <li>• Consider dose adjustments as needed for age, renal impairment, comorbidities, etc.</li> <li>• Recommend the use of nondrug therapies when appropriate.</li> <li>• Be especially watchful during transitions of care. Recommend stopping medications that may no longer be needed, such as proton pump inhibitors (PPIs), pain meds, etc.</li> <li>• Educate patients about ways to decrease their risk of falls, such as improving lighting, avoiding throw rugs and other tripping hazards, etc.</li> </ul> |

| Disorder or Treatment        | Considerations for Elderly Patients and Resources  |
|------------------------------|--|
| General, continued           | <ul style="list-style-type: none"><li>• Pharmacists can provide medication therapy management (MTM) services, including comprehensive med reviews, for elderly patients. This can help identify opportunities to optimize drug therapy and prevent drug-related problems. Keep in mind that many Medicare Part D enrollees (US) are eligible.</li><li>• Use <b>shared decision making</b> to get patients/families involved in the deprescribing process. Learn more at <a href="https://www.ahrq.gov/professionals/education/curriculum-tools/shareddecisionmaking/index.html">https://www.ahrq.gov/professionals/education/curriculum-tools/shareddecisionmaking/index.html</a>.</li><li>• For deprescribing guidelines and algorithms, information pamphlets, patient decision aids, and more see <a href="http://deprescribing.org/">http://deprescribing.org/</a>.</li><li>• For more help with deprescribing see our CE, <i>Elderly Patients' Unique Medication Needs</i>.</li></ul> |
| Analgesics                   | <ul style="list-style-type: none"><li>• <b>Opioids</b> are of concern in the elderly with a history of falls or fractures.<sup>23</sup> In addition, meperidine can cause neurotoxicity, delirium cognitive impairment, and has poor oral efficacy.<sup>23</sup> Pentazocine has more CNS effects than other opioids.<sup>23</sup> But opioid discontinuation is a challenging patient care situation. See our FAQ, <i>Opioid Tapering: Tips for Success</i>, for help.</li><li>• <b>Muscle relaxants</b> have anticholinergic effects and questionable efficacy at doses tolerated in the elderly.<sup>23</sup></li></ul>   |
| Anorexia or cachexia         | <ul style="list-style-type: none"><li>• Avoid Rx appetite stimulants (e.g., megestrol, dronabinol) in the elderly. Instead optimize social support and feeding assistance.<sup>6</sup></li></ul>   |
| Anticoagulation              | <ul style="list-style-type: none"><li>• Most elderly atrial fibrillation patients qualify for an anticoagulant. See our chart, <i>A Fib Guidelines: Focus on Pharmacotherapy</i>.</li><li>• Make sure doses of anticoagulants are adjusted appropriately, such as for reduced creatinine clearance, etc. For help, see our chart, <i>Comparison of Oral Anticoagulants</i>.</li></ul>  |
| Asthma and COPD              | <ul style="list-style-type: none"><li>• To minimize the adverse effects of inhaled corticosteroids, it might be possible to taper or even stop them.<ul style="list-style-type: none"><li>• In patients with stable severe or very severe COPD, a tapered (12 week) withdrawal of an inhaled corticosteroid from a regimen also containing an inhaled long-acting beta-agonist and an inhaled long-acting anticholinergic could be considered.<sup>24</sup></li><li>• For general guidance on stepping down inhaled corticosteroids in asthma, see our toolbox, <i>Improving Asthma Care</i>.</li></ul></li></ul>  |
| Dementia<br><br>Continued... | <ul style="list-style-type: none"><li>• Most dementia patients will not benefit from dementia meds. In addition, costs and adverse effects are a concern. Reassess the use of cholinesterase inhibitors (e.g., donepezil) and memantine in elderly patients. Consider stopping drug therapy if there's no detectable benefit by three to six months, side effects are a problem, or the patient has advanced disease.<ul style="list-style-type: none"><li>• Use our chart, <i>Alzheimer's Dementia Pharmacotherapy</i>, for guidance on when to start and discontinue cholinesterase inhibitors and memantine in patients with Alzheimer's dementia.</li></ul></li><li>• Use our chart to identify <i>Drugs With Anticholinergic Activity</i>; they may worsen cognition.</li></ul>   |

| Disorder or Treatment       | Considerations for Elderly Patients and Resources  |
|-----------------------------|--|
| <b>Dementia</b> , continued | <ul style="list-style-type: none"> <li>• Avoid antipsychotics for behavioral symptoms with dementia, due to increased risks of stroke and death. Reserve them for patients who have disturbing hallucinations or patients who exhibit dangerous behaviors. <ul style="list-style-type: none"> <li>• For help identifying antipsychotic alternatives see our chart, <i>Pharmacotherapy of Dementia Behaviors</i>.</li> </ul> </li> </ul>  |
| <b>Diabetes</b>             | <ul style="list-style-type: none"> <li>• For some elderly patients, quality of life and reducing med burden may be more important than preventing long-term complications of diabetes. Plus, hypoglycemia may lead to falls, cognitive impairment, and cardiac events.<sup>2</sup></li> <li>• Consider using the “4S” pathway to simplify and deprescribe diabetes regimens in older adults. <ul style="list-style-type: none"> <li>○ <b>Seek triggers or red flags</b> for re-evaluation of goals or strategies. Examples: unintended weight loss on GLP-1 agonist, polyuria, new or worsening urinary incontinence, hypoglycemia symptoms, falls, new comorbidity, psychosocial challenge, change in living situation).<sup>26</sup></li> <li>○ Use <b>shared decision-making</b> to discuss risks and benefits.<sup>26</sup></li> <li>○ <b>Set or re-set goals.</b><sup>26</sup> Consider an A1C goal of 7.1% to 8.5% for frail elderly, limited life expectancy, recurrent severe hypoglycemia, hypoglycemia unawareness, dementia, decline in clinical or psychosocial status, or change in living situation.<sup>27</sup> Diabetes Canada has a decision tool for individualizing your patient’s A1C target at <a href="https://www.diabetes.ca/managing-my-diabetes/tools---resources/individualizing-your-patient%E2%80%99s-a1c-target">https://www.diabetes.ca/managing-my-diabetes/tools---resources/individualizing-your-patient%E2%80%99s-a1c-target</a>.</li> <li>○ <b>Simpler or SAFER treatment.</b><sup>26</sup> <ul style="list-style-type: none"> <li>▪ Consider stopping or reducing the dose of the diabetes med most likely associated with the red flag identified in the “seeking triggers and red flags” step, above.<sup>26</sup> For example, if hypoglycemia is the problem, stop or adjust sulfonylurea or insulin (e.g., give basal insulin in the AM if hypoglycemia occurs overnight).<sup>26</sup></li> <li>▪ Monitor kidney function and check that meds are used at lower doses or avoided as appropriate.<sup>26,28</sup> For example in severe kidney impairment, reassess use of metformin, sulfonylureas, and SGLT2 inhibitors.<sup>26</sup> For details, see our infographic, <i>Drugs for Type 2 Diabetes</i>.</li> </ul> </li> </ul> </li> <li>• An evidence-based antihyperglycemic deprescribing guideline is available at <a href="http://www.cfp.ca/content/63/11/832">http://www.cfp.ca/content/63/11/832</a>. A deprescribing algorithm is available at <a href="http://deprescribing.org/wp-content/uploads/2017/11/AHG-deprescribing-algorithms-2017-English.pdf">http://deprescribing.org/wp-content/uploads/2017/11/AHG-deprescribing-algorithms-2017-English.pdf</a>.</li> </ul> |
| <b>Dyslipidemia</b>         | <ul style="list-style-type: none"> <li>• Older patients with CV disease are most likely to benefit from statin use. Per US cholesterol guidelines, for patients &gt;75 years with CV disease, use a moderate-intensity statin (e.g., atorvastatin 20 mg) to limit side effects or interactions. However, don’t back off of a high-intensity statin (e.g., atorvastatin 80 mg) if it is well tolerated. (Canadian subscribers can see our chart, <i>Canadian Dyslipidemia Recommendations</i>, for Canadian-specific recommendations.)</li> <li>• There’s less evidence of statin benefit in patients &gt;75 years without CV disease. Consider backing off for side effects, interactions, etc. Suggest stopping statins in patients with advanced dementia or life expectancy &lt;1 year.<sup>10,11</sup></li> <li>• Reevaluate the use of non-statins (e.g., niacin, fibrates). There’s no proof they further improve CV outcomes when added to a statin and they can have side effects such as gastrointestinal issues, hyperglycemia, etc.</li> </ul>  |

| Disorder or Treatment             | Considerations for Elderly Patients and Resources  |
|-----------------------------------|--|
| <b>Gastrointestinal Disorders</b> | <ul style="list-style-type: none"> <li>• <b>PPIs</b> are often overused and are associated with a number of side effects including increased risk of infections, increased risk of fractures, and electrolyte deficiencies. <ul style="list-style-type: none"> <li>• Consider whether there is a true indication for PPI use.</li> <li>• Taper the dose of a PPI to the lowest effective dose needed to achieve therapeutic goals.<sup>7</sup></li> <li>• For more tips, see our chart, <i>Proton Pump Inhibitors: Appropriate Use and Safety Concerns</i>.</li> <li>• For an evidence-based PPI deprescribing guideline see <a href="http://www.cfp.ca/content/63/5/354">http://www.cfp.ca/content/63/5/354</a>.</li> <li>• A decision aid to help you discuss PPI discontinuation with patients is available at <a href="http://deprescribing.org/wp-content/uploads/2017/10/PPI-Consult-PtDA-Oct-11-v2-wt.pdf">http://deprescribing.org/wp-content/uploads/2017/10/PPI-Consult-PtDA-Oct-11-v2-wt.pdf</a>.</li> </ul> </li> <li>• Despite its widespread use, there is not good evidence that <b>docosate</b> is effective for preventing or treating constipation. For alternatives see our algorithm, <i>Treatment of Constipation in Adults</i>.</li> </ul> |
| <b>Hypertension</b>               | <ul style="list-style-type: none"> <li>• Use clinical judgement in setting blood pressure goals and consider patient preference in those with multiple comorbidities, falls, dementia, inability to live independently, orthostasis, Parkinson’s disease, or limited life expectancy.<sup>12</sup></li> <li>• In the absence of compelling indications, beta-blockers are not first-line agents for hypertension per US guidelines.<sup>12-14</sup> (In Canada, beta-blockers are considered a first-line option for patients &lt;60 years old.)<sup>20</sup> Atenolol should be avoided because it does not improve CV outcomes.<sup>12</sup></li> <li>• For help choosing pharmacotherapy for hypertension see our chart, <i>Treatment of Hypertension (US)</i>, or our algorithm, <i>Stepwise Treatment of Hypertension (Canada)</i>.</li> </ul>  |
| <b>Insomnia</b>                   | <ul style="list-style-type: none"> <li>• Sleep problems in the elderly are common, and associated with impaired cognition and performance, fatigue, and trauma.<sup>3</sup></li> <li>• Optimize therapy of contributing medical conditions (e.g., depression, pain).<sup>3</sup> Consider eliminating, or changing the dose or timing of, contributing medications (e.g., stimulants, diuretics).<sup>3</sup></li> <li>• Targeted sleep hygiene measures are preferred to pharmacotherapy. Continue these even if pharmacotherapy is needed.<sup>3</sup></li> <li>• When pharmacotherapy is needed, consider nonbenzodiazepine options (e.g., low-dose trazodone, ramelteon [US]).<sup>15,16,18,19,25</sup> <ul style="list-style-type: none"> <li>• Our <i>Benzodiazepine Toolbox</i> provides tips for tapering oral benzodiazepines.</li> </ul> </li> <li>• Use all sedatives cautiously in the elderly due to the risk of falls, fractures, car accidents, etc.<sup>16</sup> Start with half the usual adult dose, and short duration.<sup>4</sup> For more information to help you choose a treatment for insomnia, see our chart, <i>Comparison of Insomnia Treatments</i>.</li> </ul>   |

| <b>Disorder or Treatment</b>    | <b>Considerations for Elderly Patients and Resources</b>   |
|---------------------------------|--|
| <b>Osteoporosis</b>             | <ul style="list-style-type: none"> <li>• Since the introduction and subsequent widespread, long-term use of bisphosphonates, a number of less common, potentially serious adverse effects such as atypical fractures and esophageal cancer have been noted. This has raised questions regarding the optimal duration of use.</li> <li>• Consider stopping oral bisphosphonates after five years.<sup>21</sup> Consider longer treatment for patients at high-risk of fractures.<sup>21</sup></li> <li>• Continue to suggest adequate calcium and vitamin D.<sup>21</sup></li> <li>• Our chart has more information on <i>Managing Osteoporosis: Screening, Treatment, and More</i>. We also have a CE, <i>Osteoporosis Treatment Options</i>.</li> </ul> |
| <b>Testosterone replacement</b> | <ul style="list-style-type: none"> <li>• Data supporting the efficacy of testosterone replacement therapy for older men are sketchy at best. Anecdotal reports have included men who feel more energetic or younger and small studies have shown some benefit with testosterone replacement therapy, but the long-term effects of testosterone and long-term outcomes in aging men remain unknown.<sup>5</sup></li> <li>• For more information on the advantages, disadvantages and monitoring, see our chart, <i>Comparison of Testosterone Products</i>.</li> </ul>  |
| <b>Urinary incontinence</b>     | <ul style="list-style-type: none"> <li>• Anticholinergics can have side effects that are particularly undesirable in the elderly such as delirium, cognitive impairment, dry mouth, constipation, hospitalization, falls, etc.<sup>22</sup> Consider other options such as behavioral therapy when appropriate. If drug therapy is needed, the newer, longer-acting overactive bladder agents may be a better option for the elderly (i.e., fewer side effects). For help choosing a relatively safer option see our chart, <i>Medications for Overactive Bladder</i>.</li> </ul>  |

**Abbreviations:** AM = morning; CV = cardiovascular.

*Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.*

## References

- Wallis KA, Andrews A, Henderson M. Swimming Against the Tide: Primary Care Physicians' Views on Deprescribing in Everyday Practice. *Ann Fam Med*. 2017 Jul;15(4):341-346.
- American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025. *Diabetes Care*. 2025 Jan 1;48(Supplement\_1):S128-S145.
- Kamel NS, Gammack JK. Insomnia in the elderly: cause, approach, and treatment. *Am J Med*. 2006 Jun;119(6):463-9.
- Wolkove N, Elkholy O, Baltzan M, Palayew M. Sleep and aging: 2. Management of sleep disorders in older people. *CMAJ*. 2007 May 8;176(10):1449-54.
- Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2010 Jun;95(6):2536-59. Erratum in: *J Clin Endocrinol Metab*. 2021 Jun 16;106(7):e2848.
- Choosing Wisely. American Geriatrics Society releases second Choosing Wisely list: identifies 5 more tests and treatments that older patients and providers should question. February 27, 2014. <http://www.choosingwisely.org/american-geriatrics-society-releases-second-choosing-wisely-list-identifies-5-more-tests-and-treatments-that-older-patients-and-providers-should-question/>. (Accessed August 15, 2022).
- Choosing Wisely. American Gastroenterological Association. Reviewed 2016. <http://www.choosingwisely.org/doctor-patient-lists/american-gastroenterological-association/>. (Accessed August 15, 2022).
- Reeve E, Thompson W, Farrell B. Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. *Eur J Intern Med*. 2017 Mar;38:3-11.
- American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus, Moreno G, Mangione CM, et al. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update. *J Am Geriatr Soc*. 2013 Nov;61(11):2020-6.
- Holmes HM, Sachs GA, Shega JW, et al. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. *J Am Geriatr Soc*. 2008 Jul;56(7):1306-11.
- Kutner JS, Blatchford PJ, Taylor DH et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med*. 2015 May;175(5):691-700. Erratum in: *JAMA Intern Med*. 2015 May;175(5):869. Erratum in: *JAMA Intern Med*. 2019 Jan 1;179(1):126-127.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018 Jun;71(6):e13-e115. Erratum in: *Hypertension*. 2018 Jun;71(6):e140-e144.
- James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb 5;311(5):507-20. Erratum in: *JAMA*. 2014 May 7;311(17):1809.
- Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. *J Hypertens*. 2014 Jan;32(1):3-15.
- Wiegand MH. Antidepressants for the treatment of insomnia: a suitable approach? *Drugs*. 2008;68(17):2411-7.
- American Geriatrics Society. Choosing Wisely. Don't use benzodiazepines or other sedative-hypnotics in older adults as first choice for insomnia, agitation or delirium. Revised April 23, 2015. <http://www.choosingwisely.org/clinician-lists/american-geriatrics-society-benzodiazepines-sedative-hypnotics-for-insomnia-in-older-adults/>. (Accessed August 15, 2022).
- Steinman MA, Hanlon JT. Managing medications in clinically complex elders: "There's got to be a happy medium". *JAMA*. 2010 Oct 13;304(14):1592-601.
- Clinical Resource, Comparison of Insomnia Treatments. Pharmacist's Letter/Prescriber's Letter. June 2022. [380603].
- Bemben NM. Deprescribing: An Application to Medication Management in Older Adults. *Pharmacotherapy*. 2016 Jul;36(7):774-80.
- Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. *Can J Cardiol*. 2020 May;36(5):596-624.
- Clinical Resource, Managing Osteoporosis: Screening, Treatment, and More. Pharmacist's Letter/Prescriber's Letter. October 2020.
- Clinical Resource, Drugs With Anticholinergic Activity. Pharmacist's Letter/Prescriber's Letter. September 2022.
- Clinical Resource, Potentially Harmful Drugs in the Elderly: Beers List. Pharmacist's Letter/Prescriber's Letter. March 2019.
- Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *N Engl J Med*. 2014 Oct 2;371(14):1285-94.
- Zammit G, Wang-Weigand S, Rosenthal M, Peng X. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. *J Clin Sleep Med*. 2009 Feb 15;5(1):34-40.

26. Munshi M, Kahkoska AR, Neumiller JJ, et al. Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies. *Lancet Diabetes Endocrinol.* 2025 Feb 17:S2213-8587(24)00372-3. Erratum in: *Lancet Diabetes Endocrinol.* 2025 Mar 12:S2213-8587(25)00071-3.
27. Diabetes Canada Clinical Practice Guidelines Expert Committee; Imran SA, Agarwal G, et al. Targets for Glycemic Control. *Can J Diabetes.* 2018 Apr;42 Suppl 1:S42-S46.
28. American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Care in Diabetes-2025. *Diabetes Care.* 2025 Jan 1;48(Supplement\_1):S266-S282.

***Cite this document as follows: Clinical Resource, Chronic Meds in the Elderly: Taking a “Less Is More” Approach. Pharmacist’s Letter/Prescriber’s Letter. August 2022. [380823]***

—To access hundreds more clinical resources like this one, visit [trchealthcare.com](https://trchealthcare.com) to log in or subscribe—